Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will
receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior
to vitrectomy and one intraoperative IAI at end of surgery followed by randomization in a 1:1
ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI
for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by
mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).